+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07841990

Evaluating Weekly Long-Acting Oral HIV-1 Treatments Versus Daily Therapy in People with Controlled HIV-1 Infection Substudy-01 of a Phase 2 Open-Label Trial

Led by Gilead Sciences · Updated on 2026-10-23

125

Participants Needed

2

Research Sites

308 weeks

Total Duration

AI-Summary

What This Trial Is About

This trial investigates long-acting oral regimens for people with HIV-1 who have controlled virus levels. The study focuses on evaluating safety, tolerability, effectiveness, and how the body processes these regimens compared to continuing a daily oral treatment. It specifically examines switching to weekly long-acting oral combinations including GS-3242 plus Lenacapavir versus continuing the daily oral combination of bictegraviremtricitabinetenofovir alafenamide BFTAF. Participants are assigned to one of three groups continuing daily BFTAF for at least 48 weeks, or switching to one of two doses of the weekly oral GS-3242 plus Lenacapavir regimen for at least 48 weeks. After this randomized phase, participants may have the option to continue receiving their assigned study treatment during an extension phase. Throughout the study, participants provide blood samples to monitor HIV-1 RNA levels, CD4 cell counts, and drug levels in the body. Researchers assess safety by tracking adverse events and measure how well the virus remains suppressed at weeks 12, 24, and 48. The total study duration includes at least 48 weeks of treatment, with ongoing follow-up, to evaluate the long-term effects and tolerability of the regimens.

CONDITIONS

Brief Title

Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels

Research Team

G

Gilead Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here